Vitexin

Vitexin

SCHEMBL10013309

O=c1cc(-c2ccc(O)cc2)oc2c(C3O[C@H](CO)[C@H](O)[C@H](O)[C@@H]3O)c(O)cc(O)c12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 5/20 1.00
CYP1A2 P05177 1/20 1.00
GAA P10253 5/20 0.83
KDM4E B2RXH2 5/20 0.83
POLB P06746 4/20 0.83
APEX1 P27695 4/20 0.83
TDP1 Q9NUW8 4/20 0.83
MEN1 O00255 3/20 0.83
KMT2A Q03164 3/20 0.83
ALDH1A1 P00352 3/20 0.83
MAPT P10636 2/20 0.83
THRB P10828 1/20 0.83
NTSR1 P30989 1/20 0.74
RECQL P46063 1/20 0.74
SYNJ2 O15056 1/20 0.68
AKR1B1 P15121 1/20 0.62
SMN1; SMN2 Q16637 1/20 0.60
SLCO2B1 O94956 1/20 0.60
TNF P01375 1/20 0.60
PTPN1 P18031 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Vitexin SCHEMBL4469474 1.00 L3MBTL1 (1.00) L3MBTL1CYP1A2GAAKDM4EPOLB
Vitexin SCHEMBL29572351 1.00 L3MBTL1 (1.00) L3MBTL1CYP1A2GAAKDM4EPOLB
Vitexin SCHEMBL2741236 1.00 L3MBTL1 (1.00) L3MBTL1CYP1A2GAAKDM4EPOLB
Vitexin SCHEMBL10307510 1.00 L3MBTL1 (1.00) L3MBTL1CYP1A2GAAKDM4EPOLB
Vitexin SCHEMBL25277 1.00 L3MBTL1 (1.00) L3MBTL1CYP1A2GAAKDM4EPOLB
Vitexin SCHEMBL6073075 0.91 L3MBTL1 (0.82) L3MBTL1CYP1A2GAAKDM4EPOLB
Orientin SCHEMBL30799311 0.91 L3MBTL1 (1.00) L3MBTL1CYP1A2GAAKDM4EPOLB
Orientin SCHEMBL13059270 0.91 L3MBTL1 (1.00) L3MBTL1CYP1A2GAAKDM4EPOLB
Orientin SCHEMBL29687058 0.91 L3MBTL1 (1.00) L3MBTL1CYP1A2GAAKDM4EPOLB
Orientin SCHEMBL10307494 0.91 L3MBTL1 (1.00) L3MBTL1CYP1A2GAAKDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367622-B2 Sulfated C-glycoside, method for isolating same and method for synthesizing same SHIZUOKA PREFECTURE PUBLIC UNIVERSITY CORPORATION (JP) 2013-02-05 US disclosed
US-20120029183-A1 SULFATED C-GLYCOSIDE, METHOD FOR ISOLATING SAME AND METHOD FOR SYNTHESIZING SAME SHIZUOKA PREFECTURE PUBLIC UNIVERSITY CORPORATION (JP) 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120029183-A1 SULFATED C-GLYCOSIDE, METHOD FOR ISOLATING SAME AND METHOD FOR SYNTHESIZING SAME ADH1C, ADH1A, CYP21A2 L3MBTL1 4123/4885CYP1A2 51/4885GAA 2052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.